MAWAG
RXRX icon

Mid-American Wealth Advisory Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Mid-American Wealth Advisory Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-511
Closed -$2.59K – 259
2025
Q2 		$2.59K Buy
+511
New +$2.51K ﹤0.01% 258

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mid-American Wealth Advisory Group's RXRX Position: Q3 2025 in Review

Mid-American Wealth Advisory Group sold out of Recursion Pharmaceuticals (RXRX) in Q3 2025, closing a stake of 511 shares — an estimated $2.59K sold.

Mid-American Wealth Advisory Group first reported a position in RXRX in Q2 2025 and held it in 1 quarter. The position peaked at $2.59K in Q2 2025. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • Mid-American Wealth Advisory Group reported no remaining Recursion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Mid-American Wealth Advisory Group sold 511 Recursion Pharmaceuticals shares in Q3 2025, an estimated $2.59K.
  • Mid-American Wealth Advisory Group first reported a position in Recursion Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Mid-American Wealth Advisory Group's Recursion Pharmaceuticals position peaked at $2.59K in Q2 2025.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Mid-American Wealth Advisory Group's 13F filing for Q3 2025, filed 20 Oct 2025.